EverSource Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

EverSource Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$225K	Sell	3,926 -2,919	-43%	-$160K	0.01%	948
2026 Q1	$387K	Buy	6,845 +752	+12%	+$43.8K	0.01%	720
2025 Q4	$362K	Sell	6,093 -1,058	-15%	-$57.6K	0.01%	670
2025 Q3	$387K	Buy	7,151 +235	+3%	+$13.4K	0.02%	603
2025 Q2	$380K	Buy	6,916 +5,479	+381%	+$323K	0.02%	557
2025 Q1	$102K	Buy	1,437 +803	+127%	+$54K	0.01%	906
2024 Q4	$41.7K	Buy	634 +531	+516%	+$35.6K	﹤0.01%	1269
2024 Q3	$7.24K	Buy	103 +5	+5%	+$418	﹤0.01%	2047
2024 Q2	$8.26K	Buy	98 +9	+10%	+$749	﹤0.01%	1962
2024 Q1	$7.19K	Buy	+89	New	+$7.97K	﹤0.01%	1857
2023 Q3	–	Sell	-97	Closed	-$8.41K	–	2520
2023 Q2	$8.41K	Buy	97 +17	+21%	+$1.6K	﹤0.01%	1519
2023 Q1	$7.78K	Buy	+80	New	+$8.29K	﹤0.01%	1472
2022 Q1	–	Sell	-30	Closed	-$3K	–	1712
2021 Q4	$3K	Buy	+30	New	+$2.48K	﹤0.01%	1396

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

EverSource Wealth Advisors's BMRN Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 43% in Q2 2026, selling an estimated $160K and leaving 3,926 shares worth $225K. The position accounts for 0.01% of the portfolio, ranked #948.

EverSource Wealth Advisors first reported a position in BMRN in Q4 2021 and has held it in 13 quarters since. The position peaked at $387K in Q3 2025. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

EverSource Wealth Advisors held 3,926 shares of BioMarin Pharmaceuticals worth $225K as of Q2 2026.
EverSource Wealth Advisors sold 2,919 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $160K.
BioMarin Pharmaceuticals made up 0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #948 holding.
EverSource Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
EverSource Wealth Advisors's BioMarin Pharmaceuticals position peaked at $387K in Q3 2025.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.